ImmunityBio Insurance Coverage of ANKTIVA® Across Multiple States

 

• Multiple patients treated across the U.S. with ANKTIVA less than eight weeks after FDA approval of first-in-class cytokine immunotherapy for BCG unresponsive non-muscle invasive bladder cancer
• ANKTIVA launch initiates the next era of immunotherapy beyond checkpoint inhibitors that is based on cytokines and natural killer (NK) cells
• ANKTIVA’s novel mechanism of action activates the body’s immune system of natural killer and killer T cells to attack BCG resistant tumor cells and induce memory T cells resulting in a long duration of complete response exceeding 47 months1
• ANKTIVA reimbursement now covered by multiple healthcare plans
• Urologists treating eligible bladder cancer patients can learn more about the treatment option and access support program ImmunityBio CARE™ at Anktiva.com

https://www.businesswire.com/news/home/20240620264106/en/